Harford. Officer, Thank Commercial us Pamela you, who Horn; Stephenson; Medical Chief thanks our with of me Albireo’s Chief have all and this Financial you Paul, and to joined is Virtually Pat Simon Officer, morning. Officer, our Chief Dr.
few the we call a like on received. into to key differently to do update I’d the our provide have deeper would We then an into questions little I and like slightly today. will programs you go
been So on first, obviously virus the everyone’s mind. COVID-XX has
recommendations following the monitoring and We have the of authorities. been situation
the and of the priority top commitment working are serve. to to we health is Our our patients safety employees and our
virtually, been would working of and level engagement I that Our remarkable. productivity and to has say, the used organization is
continue business needed. to as forward the solving We move problem
NASH and in ongoing Furthermore, is that programs. clinical trial are sufficient we there were clinical fortunate inventory these PFIC are trials that our conduct two of fully We recruiting enrolled. to material
million strong trials and we of the our the runway second $XX our our cash unchanged. we and into the raised to potential cash COVID-XX the clinical early and quarter, remain regarding and half of crisis Having evolution business, in monitor fundamentals to the have continue cash us get XXXX. remain impact prior sufficient position our to guidance Though is unchanged,
in the into is with PEDFIC The away X a of odevixibat data. planned update expect XX enrolled PFIC, the in XX on trial of months Starting pivotal move the Let’s fully results middle trial are topline topline our year. out from and brief just programs. with of readout we our we patients a
having full it less risk our would have -- enrollment than achieved clinical it the of ago. With been current significant trials adequate months supply, is case and COVID-XX been drug have the clinical already couple with would a
than are three-quarters of indicated trial, than completed which at excellent the more we versus more two-thirds. PEDFIC And progress most that when have our is recent update we the patients X
in the patients we remaining our While the to taking ability trial, collect of protect the confident to the are care safety utmost in data.
COVID-XX believe smartphone-like Why a is tool endpoint, with and we data the do remotely since unchanged For pruritus we the U.S. collect this? the this began. primary crisis
prioritized is the For away are blood trial remaining endpoint, maybe that the the that emergency life-saving a as trial and given settings. often are collect primary these samples EU this often serum the hospitals bile odevixibat to therapy expect from children’s we in acid rooms sites of many
we to forward launch stretch home a each second on has half are We will Thus implement job we the may really situation far, for other the case-by-case sites a now For where this the and team look doing in workarounds. in may of XXXX. our there approval not be not addressing great few -- potential data been the where the basis of case, collection.
are for submissions groundwork we meantime, launch the laying our In the regulatory and commercial accelerating preparations.
to planning, fall packaging a U.S. XXXX. patient in EU, execute with the partner for excellent with our chain the and help collaboration executing and our to patient select the continue plan in physician program, the and supply manufacturing partners make We of us on selected progress deepening communities, agreed FDA support CMC the
We in and our Phase studies stability. on are are the III planned batches commercial formulation using registration
the pivotal of now BOLD is in and Odevixibat So liver trial, biliary moving underway. biliary disease, treating use atresia. The atresia
precedent trial are We pivotal clinical announce to for trial. initiated this setting first the sites very pleased have that we
site Regarding we are the year, will part work period. for would that hospitals plan of In site during in this remotely resumed and by activation to but latter hope we stage the be of the some time. in COVID-XX, visits, would initiation access have that we conduct most the
atresia placebo-controlled to to randomized, odevixibat children double-blind, to biliary a safety evaluate the compared plan sites patients. who target with study We procedure. a undergone approximately initiate an is have in of BOLD Kasai with efficacy globally with placebo XX XXX XX and of enrollment
common the designation other both represents the liver orphan commercial FDA significant opportunity. a helpful most odevixibat population, atresia. the EMA disease This study biliary patient modification that and will the stakeholders, the be rare to data granted payers given pediatric disease provide have it is cholestatic atresia on will and Biliary in and size valuable of
when Alagille we like PFIC We pivotal more is at pivotal trial finalized. designand received this be be than details looking more But trial will quickly FDA feedback atresia the on the will Now the trial sharing design biliary syndrome. trial. our
the data by be of the topline the between topline announcement the Alagille Alagille available the to atresia PFIC We and biliary results. year to continue beginning end of program anticipate expect and pivotal
both XXX odevixibat the U.S. be will all very these hepatologists familiar physicians and and investigators There in participating are Albireo. programs with key Many these pivotal approximately three Europe. of pediatric and in be will
of trial elobixibat XX planned NAFLD patients our adult and first II of disease. to liver in shifting NASH XX full NASH. out So a in announced in we with our QX, enrollment efforts and In Phase
continue by data expect middle year. the topline of this We to
of COVID-XX. ever is the combination This during study in we inhibitor are help of positive Most conducted IBAT first-ever and the study markers, trends and GI favorable cardiovascular factors in are with study sites tolerability. trial the continuity NAFLD NASH both than clinics for looking rather proof-of-concept hospitals, an liver should and in community-based with patients which risk the
our Japanese elobixibat addition, a In in with sponsoring study of higher dose patients Pharma using milligrams. partner, EA a is XXX XX Japan
of early We this data end by expect the next or year. year the
NASH, could studies insights will efficacy to excellent potential inform cardiovascular partner. valuable and provide These with given unmet need Now optimal of and for tolerability. next believe provide the to two development the balance approach we liver risk in the our for step potential the a convenience
offers that candidate on novel working We mechanism create a a the case for the and complete the are at preclinical partner action. combination our II compelling value the two Albireo. of of the lead We believe emerging enabling lead preclinical studies additional that with studies could elobixibat for and data IND a candidate NASH Phase create potential
commercial we will moment PEDFIC we the public given U.S. most X in data the Albireo’s that will results are a that company. position development about are as arguably talk to what rapidly is take and why confident success a like and approaching to that Finally, for critical I’d regulatory yield EU. odevixibat in event
named On our with begins in impact tool odevixibat’s the ability on our to X, of pruritus pruritus demonstrate endpoint the confidence topic measurement pruritus proprietary PEDFIC Precision. the in
Whitington rating this the III and rating rigorously caregivers four-point words, developed in patients We the It our scale it II intuitive close and study testing pictures, our with distinguishes with simple for numbers tool and each like scale with colors. in Phase Phase population a FDA. and that both consultation patient uses used
recognize and and powering trial risk taken variability length. Now trial sizing there measuring steps in may mitigate have to we this assumptions be some through pruritus
the We effect treatment have moderate response. study conservatively, powered a placebo significant and a assuming
Additionally, over study and a these powering we XX%. have assumption well made the elements to lead larger of
that As to tend any in we expect weeks. and once with XX effect consultation other would the regulatory many lengthened we over time study placebo again, diminish authorities, in to studies,
that been we disease. the believe different trial therapeutic our rating the there trials X that in primary other PEDFIC using scales, due other failed the of to severity While have endpoint reach extreme areas to have is
that Patients with measurement underpin as the use our of We results. pruritus will tell design or ease trial us better believe well the that expected compliance is high not. as tool, and either the
a success for As achieve have result, pruritus the to we a of confidence high potential our in endpoint. degree
other Why our of believe to available odevixibat inhibitor do aspiration ability first, It multiple domain developing we by inhibitors. with our to is this team’s born, is claim expertise things, the IBAT fits that IBAT first-ever commercially to Albireo elobixibat. developed best-in-class lay having from Among experience in products? develop evidenced decades the
highly Odevixibat efficacy. the consider the ever exposure. potential IBAT it safety synthesized product, and with we When is systemic potent and its must of a data minimal selective best-in-class the and think is product inhibitor supporting itself most we
of with older These Odevixibat can formulation refrigerated. with data capsules strong The or give choice small capsules consistent. for infants for a odevixibat puree clinical mixed supports daily that not can are -- do a and be to children. be convenient be given need once sprinkle
acid a acids for surgeries. mean to observed II, doses. patients four weeks, in odevixibat diversion bile what’s In is lowest the bile in those In over I, acid Phase Phase two PFIC a rate lowering which demonstrated reduction the consistent achieved III eligible study and Phase bile XX% low of diarrhea of in similar in
the and four-week sleep In acid no bile the improved during period. diarrhea odevixibat pruritus with reduced treatment addition to observed powerful reduction,
The largest and prospective, ever the trial randomized, initiated. pivotal trial placebo-controlled Phase the X III PEDFIC PFIC first is in
placebo. patients We will active XX on versus approximately analyze drug XX on
revisit of that at There’s Therefore, to Alagille data that atresia available looking or view are and to about prevalence Now to primary use population research a provide exist market how patient the estimate as I think odevixibat biliary registries proposition, size. want populations. clear no we we commercial a PFIC, resources populations. secondary and
along like We NAPPED We median rate rates emerging points as comparison the history survival study regional to incidence at natural estimating sources look and the applied way. of the published populations.
to of are as our regional partnering and U.S. our We other but part on focused broadening now EU, regions analysis are discussions. mainly the
world is estimate our patients believe rest the to in pediatric that world There a of XX,XXX. cholestatic total of excess the opportunity the current significant XX,XXX of the is we in number in and of
and the work further to have completed. we We refine details ongoing as numbers share will is these efforts
track and to and with new on both So can see significant progress deliver compelling development I year. data hope that programs throughout forward we you the progress remain made our
Simon update. it’s Simon? the pleasure call financial With that, a to over turn my to for
